USA - NASDAQ:XRAY - US24906P1093 - Common Stock
The current stock price of XRAY is 10.08 USD. In the past month the price decreased by -22.64%. In the past year, price decreased by -46.3%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 17.95 | 14.34B | ||
| SOLV | SOLVENTUM CORP | 13.02 | 13.40B | ||
| ALGN | ALIGN TECHNOLOGY INC | 13.82 | 9.69B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 22.5 | 4.96B | ||
| HAE | HAEMONETICS CORP/MASS | 15.66 | 3.62B | ||
| LNTH | LANTHEUS HOLDINGS INC | 8.86 | 3.59B | ||
| ICUI | ICU MEDICAL INC | 16.65 | 3.27B | ||
| UFPT | UFP TECHNOLOGIES INC | 25.44 | 1.69B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.31B | ||
| NEOG | NEOGEN CORP | 18.57 | 1.21B | ||
| EMBC | EMBECTA CORP | 4.84 | 827.05M | ||
| BVS | BIOVENTUS INC - A | 11.39 | 555.61M |
Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. The company is headquartered in Charlotte, North Carolina and currently employs 14,000 full-time employees. The company develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices. Its Connected Technology Solutions segment includes design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of its value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and dental professional-directed aligner solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for urinary and bowel management.
DENTSPLY SIRONA INC
13320 Ballantyne Corporate Place
Charlotte NORTH CAROLINA 28277 US
CEO: Donald M. Casey
Employees: 14000
Phone: 18445463722
Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. The company is headquartered in Charlotte, North Carolina and currently employs 14,000 full-time employees. The company develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices. Its Connected Technology Solutions segment includes design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of its value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and dental professional-directed aligner solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for urinary and bowel management.
The current stock price of XRAY is 10.08 USD. The price decreased by -1.75% in the last trading session.
DENTSPLY SIRONA INC (XRAY) has a dividend yield of 4.91%. The yearly dividend amount is currently 0.62.
XRAY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
22 analysts have analysed XRAY and the average price target is 16.19 USD. This implies a price increase of 60.64% is expected in the next year compared to the current price of 10.08.
DENTSPLY SIRONA INC (XRAY) has a market capitalization of 2.01B USD. This makes XRAY a Mid Cap stock.
You can find the ownership structure of DENTSPLY SIRONA INC (XRAY) on the Ownership tab.
ChartMill assigns a fundamental rating of 4 / 10 to XRAY. While XRAY is still in line with the averages on profitability rating, there are concerns on its financial health.
Over the last trailing twelve months XRAY reported a non-GAAP Earnings per Share(EPS) of 1.58. The EPS decreased by -14.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| Debt/Equity | 1.36 |
22 analysts have analysed XRAY and the average price target is 16.19 USD. This implies a price increase of 60.64% is expected in the next year compared to the current price of 10.08.
For the next year, analysts expect an EPS growth of 14.71% and a revenue growth -4.07% for XRAY